Ingolimod for a median of 10.three months (range three.014) totaling 524.six personyears with 163 postfingolimod initiation relapses reported for 111 individuals.Table 1 summarizes demographic and baseline clinical characteristics on the 3 fingolimod patient groups. Individuals who have been therapy naive at fingolimod get started had been younger than those switching from natalizumab (p 5 0.003). Disease duration at therapy commence differed in between all patient groups (p , 0.0001 for all comparisons). In addition, patients switching from natalizumab to fingolimod had a larger baseline EDSS (median four, IQR two) than those who were previously therapy naive (median 1.five, IQR 0; p , 0.0001), or switching from IFNb/GA (median 2.five, IQR 1.5; p , 0.0001). There were no statistically important differences in baseline EDSS scores involving the treatmentnaive and IFNb/GA groups.RRs postfingolimod commencement. To identify no matter whether there was a rise in relapse activity immediately after fingolimod initiation, RRs throughout each and every 3month period inside the 15 months preceding fingolimod initiation and inside the 9month period postfingolimod initiation were determined (figure 1). Threemonth RRs within the IFNb/GAfingolimod and naivefingolimod patient groupsTableBaseline patient qualities and relapse activity postfingolimod start out by patient groupAll groups (n five 536) Naive to fingolimod (n 5 97) 62 (63.9) 30.6 (10.3) 38.0 (12.two)cIFNb/GA to fingolimod (n 5 350) 255 (72.9) 29.9 (9.eight) 40.2 (10.8) eight.7 (four.43.7)c 2.five (1.5)eNatalizumab to fingolimod (n five 89) 60 (67.4) 29.9 (9.7) 43.two (9.7)cp Value between groups 0.188a 0.826b 0.005b ,0.0001d ,0.0001dFemale, n ( ) Age at MS onset, y, mean (SD) Age at fingolimod start off, y, mean (SD) Disease duration at fingolimod commence, y, median (IQR) EDSS at fingolimod start out, median (IQR) Place, n ( ) Australia Canada Italy Kuwait Spain Other Followup time, patientyears Followup months, median (IQR) Prior remedy duration, y, median (IQR) Individuals relapsing on fingolimod, n ( ) Very first three months 3 months 6 months Total followup377 (70.117565-57-8 Chemical name 3) 30.BuyPyrrolidine Hydrochloride 0 (9.9) 40.3 (11.0) 8.six (four.24.two)four.three (1.7.eight)c 1.five (0.five)c12.8 (7.77.two)c four (2)c,e2.5 (1.5.5)304 (56.7) 36 (6.7) 42 (7.eight) 46 (8.6) 84 (15.7) 24 (four.5) 524.6 10.3 (six.24.9) 44 (45.4) 7 (7.2) 3 (three.1) 14 (14.four) 19 (19.six) 10 (10.three) 167.0 12.three (8.08.two) c196 (56.0) 26 (7.four) 36 (ten.three) 30 (8.six) 48 (13.7) 14 (4.0) 300.9 10.0 (six.44.9)c64 (71.9) 3 (3.four) three (3.4) two (2.2) 17 (19.1) 0 (0) 56.7 7.six (four.22.three)c 2.65 (1.90.26) ,0.0001d2.96 (1.58.66)41 (7.six) 18 (4.four) 16 (five.2) 111 (20.7)7 (7.2) 1 (1.two) 3 (4.3) 18 (18.6)c27 (7.7) 12 (4.five) ten (5.0) 75 (21.PMID:23522542 4)7 (7.9) five (9.three)c0.983d 0.01d 0.894d 0.813d3 (7.9) 18 (20.two)Abbreviations: EDSS five Expanded Disability Status Scale; GA 5 glatiramer acetate; IFN five interferon; IQR 5 interquartile variety; MS five a number of sclerosis. a Pearson x2 test. b Oneway analysis of variance with Bonferroni post hoc test. c Substantial comparisons. d KruskalWallis rank sum test with Bonferroni post hoc test. e Considerable comparisons. 1206 Neurology 82 April eight,FigureRelapse rate by patient group pre and postfingolimod initiationRelapse rates (imply six SEM) per 3month interval in the 15 months preceding fingolimod (FTY) get started and within the 9 months following fingolimod initiation by patient group. This figure demonstrates that the relapse price of patients switching from natalizumab (NAT) remains fairly stable on fingolimod, with no shortterm exacerbation of relapse rate. Individuals switching from interferonb (IFNb)/glatiramer acetate (GA) or who have been p.